Pfizer to join Human Vaccines Project

Biopharmaceutical giant Pfizer Inc. has announced it is to join the Human Vaccines Project focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection.

“Over the last decade, we’ve seen unprecedented technological advances in our understanding of the biology of diseases, and new tools in designing vaccines including therapeutic vaccines,” said Kathrin U. Jansen, Ph.D., senior vice president and head of vaccines research & development at Pfizer.
Of Pfizer’s decision to join the Human Vaccines Project, she added: “The translation from preclinical to clinical vaccine research has often been hampered by a lack of understanding of the desired human immune responses required to obtain optimal vaccine protection. With our strong heritage of translating scientific findings into the development of medicines and vaccines, Pfizer is proud to contribute to the consortium’s research efforts.”
By Pooling knowledge and resources from academia, government and industry, the consortium’s aim is to improve vaccines against diseases such as flu, dengue, HIV and cancer.
Founder of the Human Vaccines Project, Wayne C. Koff, Ph.D., welcomed Pfizer to the growing list of partners, which includes the Robert Wood Johnson Foundation, Regeneron, GSK, Aeras, MedImmune, Vanderbilt University Medical Center, and the John D. and Catherine T. MacArthur Foundation.
“We look forward to Pfizer’s contribution to the Human Vaccines Project as we launch an unprecedented public-private partnership in human immunology discovery, to decipher the human immunome and principles of protective immunity, to usher in a new era in global disease prevention.
“The human immune system holds the key to preventing and controlling a broad spectrum of infectious diseases, cancers, autoimmune diseases and allergies. By bringing together leading vaccine researchers, institutions and biopharmaceutical companies, and harnessing recent technological advances in molecular and cellular biology and bioinformatics, the Project may potentially enable accelerated development of vaccines and immunotherapies for some of the most devastating diseases of our time.”

Author

Phill Allen

Managing Director

Phill is an innovative thinker particularly in fluid management. His expertise lies in ensuring the seamless flow of pharmaceutical liquid logistics, whether it's optimising current processes or pioneering new approaches.

Follow me